Obstet Gynecol. 2011 Sep;118(3):718-729. doi: 10.1097/AOG.0b013e3182310c4c.
Pregnant women have a fourfold to fivefold increased risk of thromboembolism compared with nonpregnant women (1, 2). Approximately 80% of thromboembolic events in pregnancy are venous (3), with a prevalence of 0.5–2.0 per 1,000 pregnant women (4–9). Venous thromboembolism, including pulmonary embolism, accounts for 1.1 deaths per 100,000 deliveries (3), or 9 % of all maternal deaths in the United States (10). In the developing world, the leading cause of maternal death is hemorrhage (11); however, in developed nations, where hemorrhage is more often successfully treated and prevented, thromboembolic disease is one of the leading causes of death (12). The prevalence and severity of this condition during pregnancy and the peripartum period warrant special consideration of management and therapy. Such therapy includes the treatment of acute thrombotic events and prophylaxis for those at increased risk of thrombotic events. The purpose of this document is to provide information regarding the risk factors, diagnosis, management, and prevention of thromboembolism, particularly venous thromboembolism in pregnancy.
与非孕妇相比,孕妇发生血栓栓塞的风险增加了 4 至 5 倍(1,2)。妊娠期间约 80%的血栓栓塞事件为静脉血栓(3),每 1000 名孕妇中有 5 至 2.0 例(4-9)。静脉血栓栓塞症,包括肺栓塞,每 100,000 例分娩中导致 1.1 例死亡(3),占美国所有孕产妇死亡的 9%(10)。在发展中国家,孕产妇死亡的主要原因是出血(11);然而,在出血更常得到成功治疗和预防的发达国家,血栓栓塞性疾病是导致死亡的主要原因之一(12)。这种情况在妊娠和围产期的发生率和严重程度需要特别考虑管理和治疗。这种治疗包括急性血栓性事件的治疗和对有血栓性事件风险增加的患者的预防。本文件的目的是提供有关血栓栓塞症,特别是妊娠期间静脉血栓栓塞症的风险因素、诊断、管理和预防的信息。